Lupin Launches Azilsartan Medoxomil Tablets - Lupin Ltd

Code BSE: 500257 NSE: $LUPIN Lupin Launches Azilsartan Medoxomil Tablets in the United States Global pharma major Lupin Limited today announced the launch of Azilsartan Medoxomil Tablets, 40mg and 80mg in the United States following the approval from the U.S. FDA for its Abbreviated New Drug Application. The product is bioequivalent to Edarbi of Azurity Pharmaceuticals, Inc. and indicated for the treatment of hypertension in adults to lower blood pressure. Lupin is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity.